FIELD: chemistry; biochemistry.
SUBSTANCE: invention relates to biotechnology, specifically to production of versions of the Gla domain of human factor VII or human factor VIIa, and can be used in medicine. Amino acid sequence of the FVII or FVIIa version is obtained, which differs on 1 to 15 amino acid residues with amino acid sequence of the human factor VII (hFVII) or human factor VIIa (hFVIIa), in which a negatively charged amino acid residue is introduced by substitution in position 36. Obtained variants of FVII or FVIIa are used in a composition for treating mammals with diseases or disorders, where blood clotting is desirable.
EFFECT: invention allows for producing versions of FVII or FVIIa with high clotting activity and/or high activation of factor X, compared to natural form of hFVIIa.
42 cl, 3 dwg, 5 tbl, 11 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MOLECULES SIMILAR TO FACTOR VII OR VIIA | 2001 |
|
RU2278123C2 |
| MODIFIED FACTOR VII-BASED POLYPEPTIDES AND THEREOF APPLICATION | 2008 |
|
RU2571931C2 |
| FACTOR VII CHIMERIC MOLECULES | 2010 |
|
RU2563231C2 |
| CONJUGATE OF FACTOR VII POLYPEPTIDE, METHOD OF OBTAINING IT, ITS APPLICATION AND PHARMACEUTICAL COMPOSITION CONTAINING IT | 2003 |
|
RU2362807C2 |
| METHOD OF REDUCING DIMER CONTENT IN COMPOSITION CONTAINING FACTOR VII POLYPEPTIDE BY HEAT TREATMENT | 2008 |
|
RU2483079C2 |
| MODIFIED COAGULATION FACTOR VIIa WITH EXTENDED HALF-LIFE | 2007 |
|
RU2466141C2 |
| METHOD OF OBTAINING, METHOD OF PURIFICATION AND METHOD OF STABILISATION OF FACTOR VII, IX AND X POLYPEPTIDES | 2004 |
|
RU2364626C2 |
| MODIFIED VITAMIN K DEPENDENT POLYPEPTIDES | 2005 |
|
RU2396347C2 |
| STABILISATION OF PROTEIN IN SOLUTION | 2004 |
|
RU2364609C2 |
| NEW TISSUE FACTOR ANTIBODIES AS ANTICOAGULANTS | 2003 |
|
RU2345789C2 |
